JS-K inhibits bladder tumor growth in vivo. (IMAGE)
Caption
JS-K inhibits bladder tumor growth in vivo. (A) Significant decrease in relative tumor volume (RTV) after JS-K treatment from 26 days. (B) HE staining of tumor tissue of WT and LC3B−/− mice after JS-K treatment. (C) LC3B expression was low in saline-treated UM-UC-3 tumors but significantly increased following JS-K treatment. Induction of LC3B by JS-K was weaker in LC3B-deficient tumors. (D) GPX4 was highly expressed in saline-treated tumors and significantly downregulated after JS-K treatment in both UM-UC-3 and LC3B-deficient tumors. The reduction was greater in WT tumors. (E) xCT expression was high under saline conditions but decreased significantly with JS-K treatment. The reduction was more pronounced in WT tumors than in LC3B-deficient tumors. (F) p62 levels were elevated in LC3B-deficient tumors under saline conditions, consistent with impaired autophagic flux. JS-K treatment reduced p62 expression in both WT and LC3B-deficient tumors, with a greater decrease observed in UM-UC-3 tumors. Two-way analysis of variance (ANOVA) testing with a P-value threshold of 0.05, followed by Tukey’s post-hoc testing with adjustment for multiple comparisons when indicated. ***P < 0.001, ****P < 0.0001. Data are presented as the mean ± standard deviation (SD), n = 3.
Credit
Precision Clinical Medicine
Usage Restrictions
Credit must be given to the creator.
License
CC BY